Chen Shude, Wang Hongguang, Zhang Wenzhi, Chen Jiye, Lu Peng
Department of Hepatobiliary Surgery, Affiliated Hainan Hospital of General Hospital of PLA, Sanya 572000, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2018 Aug 30;38(9):1147-1150. doi: 10.12122/j.issn.1673-4254.2018.09.21.
To compared the efficacy of laparoscopy- assisted radiofrequency ablation (LRFA) and percutaneous radiofrequency ablation (PRFA) for the treatment of hepatocellular carcinoma (HCC).
Between September, 2013 and September, 2016, a total of 60 HCC patients with 78 tumor nodules underwent LRFA (30 cases with 46 tumor nodules) and PRFA (30 cases with 32 tumor nodules) in our hospital. The patients were followed up for 3 years to compare the complete ablation rate, serious complications, recurrence rate and long-term survival rate between the two groups.
The patients receiving LRFA had a complete ablation rate of 95.65% (44/46), significantly higher than the rate of 93.75% (30/32) in PRFA group ( > 0.05). Significant differences were found between LRFA and PRFA groups in the incidence of serious complications [0 6.7% (2/30), < 0.05] and recurrence rate [13.33% (4/30) 23.33% (7/30), < 0.05]. The 1-and 3-year overall survival rates of the patients were 96.15% and 55.12% in LRFA group and 93.73% and 48.54% in PRFA group, respectively ( > 0.05).
Both LRFA and PRFA are effective for HCC treatment, but is associated with a lower recurrence rate, fewer serious complications, a better treatment safety and a better applicability for tumor in difficult locations.
比较腹腔镜辅助射频消融(LRFA)与经皮射频消融(PRFA)治疗肝细胞癌(HCC)的疗效。
2013年9月至2016年9月,我院共有60例HCC患者、78个肿瘤结节接受了LRFA(30例,46个肿瘤结节)和PRFA(30例,32个肿瘤结节)治疗。对患者进行3年随访,比较两组的完全消融率、严重并发症、复发率和长期生存率。
接受LRFA的患者完全消融率为95.65%(44/46),显著高于PRFA组的93.75%(30/32)(>0.05)。LRFA组和PRFA组在严重并发症发生率[0 vs 6.7%(2/30),<0.05]和复发率[13.33%(4/30)vs 23.33%(7/30),<0.05]方面存在显著差异。LRFA组患者的1年和3年总生存率分别为96.15%和55.12%,PRFA组分别为93.73%和48.54%(>0.05)。
LRFA和PRFA对HCC治疗均有效,但LRFA复发率更低,严重并发症更少,治疗安全性更好,对困难部位肿瘤的适用性更强。